[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

CAR-T Therapy in Haematological Malignancy Market - Global Outlook and Forecast 2021-2027

April 2021 | 104 pages | ID: C1343F4AD00EEN
Market Monitor Global

US$ 3,250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report contains market size and forecasts of CAR-T Therapy in Haematological Malignancy in Global, including the following market information:

Global CAR-T Therapy in Haematological Malignancy Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global CAR-T Therapy in Haematological Malignancy market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the CAR-T Therapy in Haematological Malignancy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global CAR-T Therapy in Haematological Malignancy Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global CAR-T Therapy in Haematological Malignancy Market Segment Percentages, By Type, 2020 (%)
  • Allogeneic
  • Autologous
China CAR-T Therapy in Haematological Malignancy Market, By Application, 2016-2021, 2022-2027 ($ millions)

China CAR-T Therapy in Haematological Malignancy Market Segment Percentages, By Application, 2020 (%)
  • Hospitals
  • Cancer Research Centers
  • Others
Global CAR-T Therapy in Haematological Malignancy Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global CAR-T Therapy in Haematological Malignancy Market Segment Percentages, By Region and Country, 2020 (%)
  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
    • Nordic Countries
    • Benelux
    • Rest of Europe
  • Asia
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Rest of Asia
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • Turkey
    • Israel
    • Saudi Arabia
    • UAE
    • Rest of Middle East & Africa
Competitor Analysis

The report also provides analysis of leading market participants including:

Total CAR-T Therapy in Haematological Malignancy Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total CAR-T Therapy in Haematological Malignancy Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:
  • Celgene (Juno Therapeutics)
  • Novartis
  • Gilead (Kite Pharma)
  • Pfizer
  • CARsgen Therapeutics
  • Autolus Therapeutics
  • Aurora BioPharma
  • Sorrento Therapeutics
  • Mustang Bio
  • Bluebird Bio
  • Collectis
  • Allogene Therapeutics
  • Celyad
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 CAR-T Therapy in Haematological Malignancy Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global CAR-T Therapy in Haematological Malignancy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CAR-T THERAPY IN HAEMATOLOGICAL MALIGNANCY OVERALL MARKET SIZE

2.1 Global CAR-T Therapy in Haematological Malignancy Market Size: 2021 VS 2027
2.2 Global CAR-T Therapy in Haematological Malignancy Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top CAR-T Therapy in Haematological Malignancy Players in Global Market
3.2 Top Global CAR-T Therapy in Haematological Malignancy Companies Ranked by Revenue
3.3 Global CAR-T Therapy in Haematological Malignancy Revenue by Companies
3.4 Top 3 and Top 5 CAR-T Therapy in Haematological Malignancy Companies in Global Market, by Revenue in 2020
3.5 Global Companies CAR-T Therapy in Haematological Malignancy Product Type
3.6 Tier 1, Tier 2 and Tier 3 CAR-T Therapy in Haematological Malignancy Players in Global Market
  3.6.1 List of Global Tier 1 CAR-T Therapy in Haematological Malignancy Companies
  3.6.2 List of Global Tier 2 and Tier 3 CAR-T Therapy in Haematological Malignancy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global CAR-T Therapy in Haematological Malignancy Market Size Markets, 2021 & 2027
  4.1.2 Allogeneic
  4.1.3 Autologous
4.2 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue & Forecasts
  4.2.1 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue, 2016-2021
  4.2.2 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue, 2022-2027
  4.2.3 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global CAR-T Therapy in Haematological Malignancy Market Size, 2021 & 2027
  5.1.2 Hospitals
  5.1.3 Cancer Research Centers
  5.1.4 Others
5.2 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue & Forecasts
  5.2.1 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue, 2016-2021
  5.2.2 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue, 2022-2027
  5.2.3 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global CAR-T Therapy in Haematological Malignancy Market Size, 2021 & 2027
6.2 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue & Forecasts
  6.2.1 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue, 2016-2021
  6.2.2 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue, 2022-2027
  6.2.3 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America CAR-T Therapy in Haematological Malignancy Revenue, 2016-2027
  6.3.2 US CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.3.3 Canada CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.3.4 Mexico CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe CAR-T Therapy in Haematological Malignancy Revenue, 2016-2027
  6.4.2 Germany CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.4.3 France CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.4.4 U.K. CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.4.5 Italy CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.4.6 Russia CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.4.7 Nordic Countries CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.4.8 Benelux CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia CAR-T Therapy in Haematological Malignancy Revenue, 2016-2027
  6.5.2 China CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.5.3 Japan CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.5.4 South Korea CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.5.5 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.5.6 India CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America CAR-T Therapy in Haematological Malignancy Revenue, 2016-2027
  6.6.2 Brazil CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.6.3 Argentina CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue, 2016-2027
  6.7.2 Turkey CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.7.3 Israel CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.7.4 Saudi Arabia CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027
  6.7.5 UAE CAR-T Therapy in Haematological Malignancy Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 Celgene (Juno Therapeutics)
  7.1.1 Celgene (Juno Therapeutics) Corporate Summary
  7.1.2 Celgene (Juno Therapeutics) Business Overview
  7.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Major Product Offerings
  7.1.4 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
  7.1.5 Celgene (Juno Therapeutics) Key News
7.2 Novartis
  7.2.1 Novartis Corporate Summary
  7.2.2 Novartis Business Overview
  7.2.3 Novartis CAR-T Therapy in Haematological Malignancy Major Product Offerings
  7.2.4 Novartis CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
  7.2.5 Novartis Key News
7.3 Gilead (Kite Pharma)
  7.3.1 Gilead (Kite Pharma) Corporate Summary
  7.3.2 Gilead (Kite Pharma) Business Overview
  7.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Major Product Offerings
  7.3.4 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
  7.3.5 Gilead (Kite Pharma) Key News
7.4 Pfizer
  7.4.1 Pfizer Corporate Summary
  7.4.2 Pfizer Business Overview
  7.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Major Product Offerings
  7.4.4 Pfizer CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
  7.4.5 Pfizer Key News
7.5 CARsgen Therapeutics
  7.5.1 CARsgen Therapeutics Corporate Summary
  7.5.2 CARsgen Therapeutics Business Overview
  7.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
  7.5.4 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
  7.5.5 CARsgen Therapeutics Key News
7.6 Autolus Therapeutics
  7.6.1 Autolus Therapeutics Corporate Summary
  7.6.2 Autolus Therapeutics Business Overview
  7.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
  7.6.4 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
  7.6.5 Autolus Therapeutics Key News
7.7 Aurora BioPharma
  7.7.1 Aurora BioPharma Corporate Summary
  7.7.2 Aurora BioPharma Business Overview
  7.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Major Product Offerings
  7.4.4 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
  7.7.5 Aurora BioPharma Key News
7.8 Sorrento Therapeutics
  7.8.1 Sorrento Therapeutics Corporate Summary
  7.8.2 Sorrento Therapeutics Business Overview
  7.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
  7.8.4 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
  7.8.5 Sorrento Therapeutics Key News
7.9 Mustang Bio
  7.9.1 Mustang Bio Corporate Summary
  7.9.2 Mustang Bio Business Overview
  7.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Major Product Offerings
  7.9.4 Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
  7.9.5 Mustang Bio Key News
7.10 Bluebird Bio
  7.10.1 Bluebird Bio Corporate Summary
  7.10.2 Bluebird Bio Business Overview
  7.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Major Product Offerings
  7.10.4 Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
  7.10.5 Bluebird Bio Key News
7.11 Collectis
  7.11.1 Collectis Corporate Summary
  7.11.2 Collectis Business Overview
  7.11.3 Collectis CAR-T Therapy in Haematological Malignancy Major Product Offerings
  7.11.4 Collectis CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
  7.11.5 Collectis Key News
7.12 Allogene Therapeutics
  7.12.1 Allogene Therapeutics Corporate Summary
  7.12.2 Allogene Therapeutics Business Overview
  7.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
  7.12.4 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
  7.12.5 Allogene Therapeutics Key News
7.13 Celyad
  7.13.1 Celyad Corporate Summary
  7.13.2 Celyad Business Overview
  7.13.3 Celyad CAR-T Therapy in Haematological Malignancy Major Product Offerings
  7.13.4 Celyad CAR-T Therapy in Haematological Malignancy Revenue in Global (2016-2021)
  7.13.5 Celyad Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES

Table 1. CAR-T Therapy in Haematological Malignancy Market Opportunities & Trends in Global Market
Table 2. CAR-T Therapy in Haematological Malignancy Market Drivers in Global Market
Table 3. CAR-T Therapy in Haematological Malignancy Market Restraints in Global Market
Table 4. Key Players of CAR-T Therapy in Haematological Malignancy in Global Market
Table 5. Top CAR-T Therapy in Haematological Malignancy Players in Global Market, Ranking by Revenue (2019)
Table 6. Global CAR-T Therapy in Haematological Malignancy Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Companies, 2016-2021
Table 8. Global Companies CAR-T Therapy in Haematological Malignancy Product Type
Table 9. List of Global Tier 1 CAR-T Therapy in Haematological Malignancy Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 CAR-T Therapy in Haematological Malignancy Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - CAR-T Therapy in Haematological Malignancy Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - CAR-T Therapy in Haematological Malignancy Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - CAR-T Therapy in Haematological Malignancy Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - CAR-T Therapy in Haematological Malignancy Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2022-2027
Table 30. Celgene (Juno Therapeutics) Corporate Summary
Table 31. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Offerings
Table 32. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2016-2021)
Table 33. Novartis Corporate Summary
Table 34. Novartis CAR-T Therapy in Haematological Malignancy Product Offerings
Table 35. Novartis CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2016-2021)
Table 36. Gilead (Kite Pharma) Corporate Summary
Table 37. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Offerings
Table 38. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2016-2021)
Table 39. Pfizer Corporate Summary
Table 40. Pfizer CAR-T Therapy in Haematological Malignancy Product Offerings
Table 41. Pfizer CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2016-2021)
Table 42. CARsgen Therapeutics Corporate Summary
Table 43. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Offerings
Table 44. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2016-2021)
Table 45. Autolus Therapeutics Corporate Summary
Table 46. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Offerings
Table 47. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2016-2021)
Table 48. Aurora BioPharma Corporate Summary
Table 49. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Offerings
Table 50. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2016-2021)
Table 51. Sorrento Therapeutics Corporate Summary
Table 52. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Offerings
Table 53. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2016-2021)
Table 54. Mustang Bio Corporate Summary
Table 55. Mustang Bio CAR-T Therapy in Haematological Malignancy Product Offerings
Table 56. Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2016-2021)
Table 57. Bluebird Bio Corporate Summary
Table 58. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Offerings
Table 59. Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2016-2021)
Table 60. Collectis Corporate Summary
Table 61. Collectis CAR-T Therapy in Haematological Malignancy Product Offerings
Table 62. Collectis CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2016-2021)
Table 63. Allogene Therapeutics Corporate Summary
Table 64. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Offerings
Table 65. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2016-2021)
Table 66. Celyad Corporate Summary
Table 67. Celyad CAR-T Therapy in Haematological Malignancy Product Offerings
Table 68. Celyad CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), (2016-2021)

LIST OF FIGURES

Figure 1. CAR-T Therapy in Haematological Malignancy Segment by Type
Figure 2. CAR-T Therapy in Haematological Malignancy Segment by Application
Figure 3. Global CAR-T Therapy in Haematological Malignancy Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global CAR-T Therapy in Haematological Malignancy Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global CAR-T Therapy in Haematological Malignancy Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by CAR-T Therapy in Haematological Malignancy Revenue in 2020
Figure 8. By Type - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2016-2027
Figure 9. By Application - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2016-2027
Figure 10. By Region - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2016-2027
Figure 11. By Country - North America CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2016-2027
Figure 12. US CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 13. Canada CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2016-2027
Figure 16. Germany CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 17. France CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 19. Italy CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 20. Russia CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2016-2027
Figure 24. China CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 25. Japan CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 28. India CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2016-2027
Figure 30. Brazil CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2016-2027
Figure 33. Turkey CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 34. Israel CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 36. UAE CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2016-2027
Figure 37. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Novartis CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Pfizer CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 45. Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 46. Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 47. Collectis CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 48. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)


More Publications